A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium

References

• Almirall J, Bolibar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000;15:757–63
   PubMed Web of Science ®Google Scholar
• Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977–88
   PubMed Web of Science ®Google Scholar
• Anderson RN. Deaths: leading causes for 2000. Natl Vital Stat Rep 2002;50:1–86
   PubMedGoogle Scholar
• Talwar A, Lee H, Fein A. Community-acquired pneumonia: what is relevant and what is not? Curr Opin Pulm Med 2007;13:177–85
   Google Scholar
• Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 2005;118(Suppl 7A);29–38
   Google Scholar
• Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820–37
   PubMed Web of Science ®Google Scholar
• Lave JR, Lin CJ, Fine MJ, et al. The cost of treating patients with community-acquired pneumonia. Semin Respir Crit Care Med 1999;20:189–97
   Web of Science ®Google Scholar
• Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000;109:378–85
   PubMed Web of Science ®Google Scholar
• Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999;159:970–80
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med 1997;336:243–50
   PubMed Web of Science ®Google Scholar
• Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377–82
   PubMed Web of Science ®Google Scholar
• Aliyu ZY, Aliyu MH, McCormick K. Determinants for hospitalization in ‘low-risk’ community acquired pneumonia. BMC Infect Dis 2003;3:11
   Google Scholar
• Carratala J, Martin-Herrero JE, Mykietiuk A, et al. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. Clin Microbiol Infect 2006;12:2–11
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138–80
   PubMed Web of Science ®Google Scholar
• Simoens S, Verhaegen J, Laekeman G, Peetermans WE. Treating respiratory tract infections in ambulatory care in Belgium: fluoroquinolone consumption and resistance development. Int J Antimicrob Agents 2005;26:62–8
   PubMed Web of Science ®Google Scholar
• Institut Pasteur. Evolution of fluoroquinolone resistance and detection of resistance mechanisms in clinical isolates of Streptococcus pneumoniae collected in Belgium in 1995–2005. Institut Pasteur. Brussels, 2006. Available at www.pasteur.be/pasteur_fr/index5930.html?page=antibiotic_research [last accessed 4 January 2008]
   Google Scholar
• File Jr TM. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004;117(Suppl 3A);39–50
   Google Scholar
• Belgian Antibiotic Policy Coordination Committee. Belgian guide for anti-infectious treatment in ambulatory practice. Brussels: Belgian Antibiotic Policy Coordination Committee; 2006
   Google Scholar
• Martin M, Quilici S, File T, et al. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother 2007;59:977–89
   PubMed Web of Science ®Google Scholar
• Valcke Y. CAP guidelines: why differences between Belgian and American/Canadian guidelines? Louvain: Université Catholique de Louvain; 2001. Available at: http://www.farm.ucl.ac.be/seminfec//Atelier-Mandell-23-11-01/Valcke/Valcke.pdf [last accessed 4 January 2008]
   Google Scholar
• Jones ME, Blosser-Middleton RS, Critchley IA, et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000–2001. Clin Microbiol Infect 2003;9:590–9
   PubMed Web of Science ®Google Scholar
• Welte T, Marre R, Suttorp N. What is new in the treatment of community-acquired pneumonia? Med Klin (Munich) 2006;101:313–20
   PubMedGoogle Scholar
• Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults [Infectious Diseases Society of America]. Clin Infect Dis 2000;31:347–82
   PubMed Web of Science ®Google Scholar
• Laurichesse H, Gerbaud L, Baud O, et al. Hospitalization decision for ambulatory patients with community-acquired pneumonia: a prospective study with general practitioners in France. Infection 2001;29:320–5
   PubMed Web of Science ®Google Scholar
• Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003;21:135–43
   PubMed Web of Science ®Google Scholar
• Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185–95
   PubMed Web of Science ®Google Scholar
• Hoeffken G, Meyer HP, Winter J, Verhoef L. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001;95:553–64
   PubMed Web of Science ®Google Scholar
• Faich GA, Morganroth J, Whitehouse AB, et al. Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann Pharmacother 2004;38:749–54
   PubMed Web of Science ®Google Scholar
• Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004;98: 708–20
   Google Scholar
• Higuera F, Hidalgo H, Feris J, et al. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996;37:555–64
   PubMed Web of Science ®Google Scholar
• Mathers DL, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48–62
   Google Scholar
• Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515–23
   PubMed Web of Science ®Google Scholar
• Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003;46: 285–9
   Google Scholar
• Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229–46
   PubMed Web of Science ®Google Scholar
• Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003;7(Suppl 1):S13–S20
   Google Scholar
• Dagan R. Achieving bacterial eradication using pharmacokinetic/ pharmacodynamic principles. Int J Infect Dis 2003;7(Suppl 1):S21–S26
   Google Scholar
• Hoban D, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother 2002;50(Suppl S1):49–59
   PubMedGoogle Scholar
• Institut Pasteur. Presence of macrolide resistance mechanisms in clinical isolates of Streptococcus pneumoniae collected in Belgium in 1995–2005. Institut PasteurP: Brussels; 2006. Available at www.pasteur.be/pasteur_fr/index5930.html?page=antibiotic_research [last accessed 30 January 2007]
   Google Scholar
• Reinert RR, Simic S, Al Lahham A, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study. J Clin Microbiol 2001;39:1187–9
   PubMed Web of Science ®Google Scholar
• Institut National d’Assurance Maladie-Invalidité (INAMI). Brussels, 2006. Available at: www.inami.fgov.be [last accessed 30 January 2007]
   Google Scholar
• Fantin B, Aubert JP, Unger P, et al. Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France. Chest 2001;120:185–92
   PubMedGoogle Scholar
• Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest 2004;125:2140–5
   PubMed Web of Science ®Google Scholar
• Programme de Médicalisation des Systèmes d’Information (PMSI). Paris, 2006. Available at: www.pmsi.fr [last accessed 30 January 2007]
   Google Scholar
• Williams D, Hopkins S. Safety of trovafloxacin in treatment of lower respiratory tract infections. Eur J Clin Microbiol InfectDis 1998;17:454–8
   PubMed Web of Science ®Google Scholar
• Flanders SA, Halm EA. Guidelines for community-acquired pneumonia: are they reflected in practice? Treat Respir Med 2004;3:67–77
   PubMedGoogle Scholar
• Singer ME, Harding I, Jacobs MR, Jaffe DH. Impact of antimicrobial resistance on health outcomes in the outpatient treatment of adult community-acquired pneumonia: a probability model. J Antimicrob Chemother 2003;51:1269–82
   PubMed Web of Science ®Google Scholar
• Sabes-Figuera R, Segu JL, Puig-Junoy J, Torres A. Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia. Eur J Health Econ 2007: published online 13 January 2007, doi: 10.1007/s10198–006–0019–0
   Google Scholar
• Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 2002;20:513–28
   Google Scholar